{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:40:25Z","timestamp":1787960425591,"version":"build-2784847793"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Soluble C\u2010type lectin\u2010like receptor 2 (sCLEC\u20102) has emerged as a biomarker of platelet activation and thrombus formation. Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and pregnancy complications, driven in part by platelet activation. However, the clinical utility of sCLEC\u20102 and the sCLEC\u20102\/D\u2010dimer ratio in APS remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma samples from 19 patients with primary APS, 30 with SLE\u2010associated APS, 10 with SLE without APS, 40 with other collagen diseases, and 40 healthy controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009139) were analyzed. Plasma sCLEC\u20102 levels and D\u2010dimer levels were quantified by immunoassay. Antiphospholipid antibodies (anti\u2010cardiolipin antibodies and anti\u2010\u03b2\n                      <jats:sub>2<\/jats:sub>\n                      \u2010glycoprotein I antibodies IgG\/IgM) were measured by ELISA kits. Group comparisons and correlations were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using the upper limit of the 95% CI of healthy controls as a cutoff, sCLEC\u20102 positivity was observed in 100% of non\u2010APS autoimmune disease patients, and 98.0% of APS patients. sCLEC\u20102, D\u2010dimer, and the sCLEC\u20102\/D\u2010dimer ratio were significantly higher in non\u2010APS and APS groups compared with controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A slight but significant difference in the sCLEC\u20102 and the ratio was observed between the non\u2010APS and APS groups. However, no significant differences were found among APS subgroups stratified by thrombosis type. sCLEC\u20102 showed no correlation with any of four major antiphospholipid antibody titers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although we observed raised sCLEC\u20102 and sCLEC\u20102\/D\u2010dimer ratio among APS and non\u2010APS groups and modest differences between the two groups, clinical interpretation of the findings requires a prospective study evaluating dynamic changes of sCLEC\u20102 in the clinical course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcla.70230","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:24:23Z","timestamp":1776417863000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Interpretation of Platelet Activation Marker\n                    <scp>sCLEC<\/scp>\n                    \u20102 in Antiphospholipid Syndrome"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-4705","authenticated-orcid":false,"given":"Risa","family":"Kaneshige","sequence":"first","affiliation":[{"name":"Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine  Ube Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-8364","authenticated-orcid":false,"given":"Yukari","family":"Motoki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine  Ube Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6039-4537","authenticated-orcid":false,"given":"Kiyoshi","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine  Ube Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-015X","authenticated-orcid":false,"given":"Junzo","family":"Nojima","sequence":"additional","affiliation":[{"name":"Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine  Ube Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2024.2420949"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702327200"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2015.1021319"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153408"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13984"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132860"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010019\u201002680\u20104"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040985"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(10)60709\u2010X"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030741"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24340"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2006.01753.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"issue":"1","key":"e_1_2_12_15_1","first-page":"30","article-title":"An Antibody That Recognizes the Human E Domain of Fibrin Bound With the D Domain, and Its Implication for the Measurement of Cross\u2010Linked Fibrin Degradation Products","volume":"18","author":"Nagahama Y.","year":"2017","journal-title":"Japanese Society for Laboratory Hematology"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296\u2010018\u20104001\u20109"},{"issue":"5","key":"e_1_2_12_17_1","first-page":"823","article-title":"Elevated Levels of Soluble CD40 Ligand Are Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus","volume":"35","author":"Kim K. J.","year":"2017","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102141.2001.03101.x"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen\u20102022\u2010002534"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.07.006"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030891"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13248"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123135"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15417"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959\u2010024\u201000594\u20108"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.70230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcla.70230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.70230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:04:43Z","timestamp":1779811483000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.70230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/jcla.70230"],"URL":"https:\/\/doi.org\/10.1002\/jcla.70230","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2026-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70230"}}